A randomised controlled trial assessing the effectiveness, safety and cost-effectiveness of methotrexate versus ciclosporin in the treatment of severe atopic eczema in children: The TREatment of Severe Atopic Eczema Trial (TREAT)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 21 Sep 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ciclosporin (Primary) ; Ciclosporin (Primary) ; Methotrexate (Primary) ; Methotrexate (Primary)
Indications Atopic dermatitis
Focus Adverse reactions; Therapeutic Use
Acronyms TREAT

Most Recent Events

19 Sep 2023 Results assessing the safety and efficacy of ciclosporin (CyA) versus methotrexate (MTX) in CYP with severe AD presented in the British Journal of Dermatology
19 Apr 2023 Status changed from active, no longer recruiting to completed.
27 Jul 2020 This trial has been completed in United kingdom as per European Clinical Trials Database record (global end of the trial 2016-12-08 )

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight